- Monthly testing volume grows 20 times in one year after export expansion
Korean IVD company SML Genetree is accelerating its global molecular diagnostics business as it makes an entry into Japan’s sexually transmitted disease (STD) testing market.
SML Genetree announced that they participated in the Japan Association of Clinical Laboratory Systems (JACLAS) exhibition and held business meetings with major partners in Japan.
During this visit, the company discussed detailed strategies to strengthen its partnership with Japanese counterparts — including joint research and development, collaborative regulatory submissions, and local manufacturing initiatives.
Japan’s STD diagnostic market is estimated at around USD 400 million as of 2023 and is expected to grow to over USD 600 million by 2030. Currently, most STD testing in Japan relies on immunodiagnostic methods and microbial cultures, which face challenges such as limited accuracy, long turnaround times, and high costs — driving demand for more efficient alternatives.
SML Genetree’s PCR-based molecular diagnostic technology is drawing attention as a next-generation solution to these limitations. By directly detecting the genetic material of pathogens, it offers high accuracy even in the early stages of infection, provides results within three hours, and maintains cost efficiency.
The company signed a partnership agreement with a Japanese firm last year, already achieving annual sales exceeding USD 100,000. With market expansion, it anticipates multi-fold growth. Initially, SML Genetree plans to penetrate the Japanese diagnostic service market through online marketing, followed by obtaining approval from the Ministry of Health, Labour and Welfare (MHLW) to expand into the IVD market.
During the Japan business trip, SML Genetree and its local partners established a framework for joint R&D, regulatory collaboration, and localized production, solidifying a foundation for long-term operations. During the JACLAS exhibition, the company also met with key figures in Japan’s diagnostic industry to explore directions for future joint projects and global business collaboration.
SML Genetree stated that Japan is an attractive market with a much larger IVD sector than Korea, and that the molecular diagnostics field remains a blue ocean with significant growth potential. The company aims to accelerate its efforts to secure an early lead in Japan’s molecular diagnostics market through this partnership.
Source: Medical News (의학신문)
http://www.bosa.co.kr/news/articleView.html?idxno=2259778
Korean IVD company SML Genetree is accelerating its global molecular diagnostics business as it makes an entry into Japan’s sexually transmitted disease (STD) testing market.
SML Genetree announced that they participated in the Japan Association of Clinical Laboratory Systems (JACLAS) exhibition and held business meetings with major partners in Japan.
During this visit, the company discussed detailed strategies to strengthen its partnership with Japanese counterparts — including joint research and development, collaborative regulatory submissions, and local manufacturing initiatives.
Japan’s STD diagnostic market is estimated at around USD 400 million as of 2023 and is expected to grow to over USD 600 million by 2030. Currently, most STD testing in Japan relies on immunodiagnostic methods and microbial cultures, which face challenges such as limited accuracy, long turnaround times, and high costs — driving demand for more efficient alternatives.
SML Genetree’s PCR-based molecular diagnostic technology is drawing attention as a next-generation solution to these limitations. By directly detecting the genetic material of pathogens, it offers high accuracy even in the early stages of infection, provides results within three hours, and maintains cost efficiency.
The company signed a partnership agreement with a Japanese firm last year, already achieving annual sales exceeding USD 100,000. With market expansion, it anticipates multi-fold growth. Initially, SML Genetree plans to penetrate the Japanese diagnostic service market through online marketing, followed by obtaining approval from the Ministry of Health, Labour and Welfare (MHLW) to expand into the IVD market.
During the Japan business trip, SML Genetree and its local partners established a framework for joint R&D, regulatory collaboration, and localized production, solidifying a foundation for long-term operations. During the JACLAS exhibition, the company also met with key figures in Japan’s diagnostic industry to explore directions for future joint projects and global business collaboration.
SML Genetree stated that Japan is an attractive market with a much larger IVD sector than Korea, and that the molecular diagnostics field remains a blue ocean with significant growth potential. The company aims to accelerate its efforts to secure an early lead in Japan’s molecular diagnostics market through this partnership.
Source: Medical News (의학신문)
http://www.bosa.co.kr/news/articleView.html?idxno=2259778